Sana Biotechnology Presents Preclinical Data Showing Surrogate SG293 Achieves Cell-Specific Delivery, Dose-Dependent CAR T Cell Generation, And Deep B Cell Depletion In NHPs At ASGCT 2026 Annual Meeting

Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in non-human primates (NHPs) without the use of lymphodepleting chemotherapy. SG293 is a CD8-targeted fusosome that delivers the genetic material to make CD19-directed CAR T cells. The data were reported in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting.